Thrombopoietin-receptor agonists for children with immune thrombocytopenia: a systematic review

References

• Rodeghiero F, Stasi R, Gernsheimer T, et al. Standardization of terminology, definitions and outcome criteria in an international working group immune thrombocytopenic purpura of adults and children: report from an international working group. Blood. 2009;113(11):2386–2393.
   PubMed Web of Science ®Google Scholar
• Kurata Y, Fujimura K, Kuwana M, et al. Epidemiology of primary immune thrombocytopenia in children and adults in Japan: a population-based study and literature review. Int J Hematol. 2011;93(3):329–335.
   PubMed Web of Science ®Google Scholar
• Moulis G, Palmaro A, Montastruc JL, et al. Epidemiology of incident immune thrombocytopenia: a nationwide population-based study in France. Blood. 2014;124(22):3308–3315.
   PubMed Web of Science ®Google Scholar
• Yong M, Schoonen WM, Li L, et al. Epidemiology of paediatric immune thrombocytopenia in the General Practice Research Database. Br J Haematol. 2010;149(6):855–864.
   PubMed Web of Science ®Google Scholar
• Lee JY, Lee JH, Lee H, et al. Epidemiology and management of primary immune thrombocytopenia: a nationwide population-based study in Korea. Thromb Res. 2017;155:86–91.
   PubMed Web of Science ®Google Scholar
• Kühne T, Buchanan GR, Zimmerman S, et al. A prospective comparative study of 2540 infants and children with newly diagnosed idiopathic thrombocytopenic purpura (ITP) from the Intercontinental Childhood ITP Study Group. J Pediatr. 2003;143(5):605–608.
   PubMed Web of Science ®Google Scholar
• Donato H, Picón A, Martinez M, et al. Demographic data, natural history, and prognostic factors of idiopathic thrombocytopenic purpura in children: a multicentered study from Argentina. Pediatr Blood Cancer. 2009;52(4):491–496.
   PubMed Web of Science ®Google Scholar
• Imbach P, Kühne T, Müller D, et al. Childhood ITP: 12 months follow-up data from the prospective registry I of the Intercontinental Childhood ITP Study Group (ICIS). Pediatr Blood Cancer. 2006;46(3):351–356.
   PubMed Web of Science ®Google Scholar
• Rosthøj S, Rajantie J, Treutiger I, et al. Duration and morbidity of chronic immune thrombocytopenic purpura in children: five-year follow-up of a Nordic cohort. Acta Paediatr. 2012;101(7):761–766.
   PubMed Web of Science ®Google Scholar
• Neunert CE, Buchanan GR, Imbach P, et al. Bleeding manifestations and management of children with persistent and chronic immune thrombocytopenia: data from the Intercontinental Cooperative ITP Study Group (ICIS). Blood. 2013;121(22):4457–4462.
   PubMed Web of Science ®Google Scholar
• Neunert C, Lim W, Crowther M, et al. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood. 2011;117(16):4190–4207.
   PubMed Web of Science ®Google Scholar
• Erhardt JA, Erickson-Miller CL, Aivado M, et al. Comparative analyses of the small molecule thrombopoietin receptor agonist eltrombopag and thrombopoietin on in vitro platelet function. Exp Hematol. 2009;37(9):1030–1037.
   PubMed Web of Science ®Google Scholar
• Garzon AM, Mitchell WB. Use of thrombopoietin receptor agonists in childhood immune thrombocytopenia. Front Pediatr. 2015;3(70):1–5.
   PubMed Web of Science ®Google Scholar
• Bussel JB, Buchanan GR, Nugent DJ, et al. A randomized, double-blind study of romiplostim to determine its safety and efficacy in children with immune thrombocytopenia. Blood. 2011;118(1):28–36.
   PubMed Web of Science ®Google Scholar
• Bussel JB, Hsieh L, Buchanan GR, et al. Long-term use of the thrombopoietin-mimetic romiplostim in children with severe chronic immune thrombocytopenia (ITP). Pediatr Blood Cancer. 2015;62(2):208–213.
   PubMed Web of Science ®Google Scholar
• Mokhtar GM, Tantawy AA, Sherif N. Romiplostim therapy in children with unresponsive chronic immune thrombocytopenia. Platelets. 2012;23(4):264–273.
   PubMed Web of Science ®Google Scholar
• Vilaplana VE, Aragonés JH, Fernándezllamazares CM, et al. Use of romiplostim for primary immune thrombocytopenia in children. Pediatr Hematol Oncol. 2012;29(2):197–205.
   PubMed Web of Science ®Google Scholar
• Pasquet M, Aladjidi N, Guiton C, et al. Romiplostim in children with chronic immune thrombocytopenia (ITP): the French experience. Br J Haematol. 2014;164:266–271.
   PubMed Web of Science ®Google Scholar
• Ramaswamy K, Hsieh L, Leven E, et al. Thrombopoietic agents for the treatment of persistent and chronic immune thrombocytopenia in children. J Pediatr. 2014;165(3):600–605.
   PubMed Web of Science ®Google Scholar
• Neunert C, Despotovic J, Haley K, et al. Thrombopoietin receptor agonist use in children: data from the pediatric ITP consortium of North America ICON2 study. Pediatr Blood Cancer. 2016;63(8):1407–1413.
   PubMed Web of Science ®Google Scholar
• Tarantino MD, Bussel JB, Blanchette VS, et al. Romiplostim in children with immune thrombocytopenia: a phase 3, randomised, double-blind, placebo-controlled study. Lancet. 2016;388(10039):45–54.
   PubMed Web of Science ®Google Scholar
• Zeng Y, Duan X, Xu J, et al. TPO receptor agonist for chronic idiopathic thrombocytopenic purpura. Cochrane Database Syst Rev. 2011;CD008235.
   PubMed Web of Science ®Google Scholar
• Neunert CE, Grace RF. Thrombopoietin-receptor agonists in children with immune thrombocytopenia. Lancet. 2015;386(10004):1606–1609.
   PubMed Web of Science ®Google Scholar
• Liang Y, Zhang L, Gao J, et al. Rituximab for children with immune thrombocytopenia: a systematic review. Plos One. 2012;7(5):e36698.
   PubMed Web of Science ®Google Scholar
• Higgins J, Green S The Cochrane Collaboration. Cochrane handbook for systematic reviews of interventions version 5.1.0. 2011. Available at: http://handbook.cochrane.org/.[Accessed 20 March 2017]
   Google Scholar
• Bussel JB, De Miguel PG, Despotovic JM, et al. Eltrombopag for the treatment of children with persistent and chronic immune thrombocytopenia (PETIT): a randomised, multicentre, placebo-controlled study. Lancet Haematol. 2015;2(8):e315–e325.
   PubMed Web of Science ®Google Scholar
• Grainger JD, Sevilla J, Blanchette VS, et al. Eltrombopag for children with chronic immune thrombocytopenia (PETIT2): a randomised, multicentre, placebo-controlled trial. Lancet. 2015;386(10004):1649–1658.
   PubMed Web of Science ®Google Scholar
• Elalfy MS, Abdelmaksoud AA, Eltonbary KY. Romiplostim in children with chronic refractory ITP: randomized placebo controlled study. Ann Hematol. 2011;90(11):1341–1344.
   PubMed Web of Science ®Google Scholar